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OBJECTIVES This study sought to hypothesize that global longitudinal strain (GLS) as a measure of
infarct size, and mechanical dispersion (MD) as a measure of myocardial deformation heterogeneity,
would be of incremental importance for the prediction of sudden cardiac death (SCD) or malignant ven-
tricular arrhythmias (VA) after acute myocardial infarction (MI).
BACKGROUND SCD after acute MI is a rare but potentially preventable late complication predom-
inantly caused by malignant VA. Novel echocardiographic parameters such as GLS and MD have previ-
ously been shown to identify patients with chronic ischemic heart failure at increased risk for arrhythmic
events. Risk prediction during admission for acute MI is important because a majority of SCD events
occur in the early period after hospital discharge.
METHODS We prospectively included patients with acute MI and performed echocardiography, with
measurements of GLS and MD deﬁned as the standard deviation of time to peak negative strain in all
myocardial segments. The primary composite endpoint (SCD, admission with VA, or appropriate therapy
from a primary prophylactic implantable cardioverter-deﬁbrillator [ICD]) was analyzed with Cox models.
RESULTS A total of 988 patients (mean age: 62.6  12.1 years; 72% male) were included, of whom 34
(3.4%) experienced the primary composite outcome (median follow-up: 29.7 months). GLS (hazard ratio
[HR]: 1.38; 95% conﬁdence interval [CI]: 1.25 to 1.53; p < 0.0001) and MD (HR/10 ms: 1.38; 95% CI: 1.24 to
1.55; p < 0.0001) were signiﬁcantly related to the primary endpoint. GLS (HR: 1.24; 95% CI: 1.10 to 1.40;
p ¼ 0.0004) and MD (HR/10 ms: 1.15; 95% CI: 1.01 to 1.31; p ¼ 0.0320) remained independently prog-
nostic after multivariate adjustment. Integrated diagnostic improvement (IDI) and net reclassiﬁcation in-
dex (NRI) were signiﬁcant for the addition of GLS (IDI: 4.4% [p < 0.05]; NRI: 29.6% [p < 0.05]), whereas MD
did not improve risk reclassiﬁcation when GLS was known.
CONCLUSIONS Both GLS and MD were signiﬁcantly and independently related to SCD/VA in these
patients with acute MI and, in particular, GLS improved risk stratiﬁcation above and beyond existing risk
factors. (J Am Coll Cardiol Img 2013;6:851–60) ª 2013 by the American College of Cardiology
Foundation
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GLS = global longitudinal
HF = heart failure
ICD = implantable cardiove
deﬁbrillator
IDI = integrated diagnostic
improvement
LVEDV = left ventricular
end-diastolic volume
LVEF = left ventricular
ejection fraction
MD = mechanical dispersio
MI = myocardial infarction
NRI = net reclassiﬁcation
improvement
SCD = sudden cardiac dea
VA = ventricular arrhythmi
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852udden cardiac death (SCD) and life-
threatening ventricular arrhythmias (VA) are
rare but devastating complications following
acute myocardial infarction (MI). Primary
prevention with an implantable cardioverter-
deﬁbrillator (ICD) is recommended in patients
with left ventricular ejection fraction (LVEF)#35%
and symptomatic congestive heart failure (HF) at
least 40 days after an acute MI (1). Although the
absolute risk for SCD is highest in patients with
signiﬁcantly reduced LVEF (2), a signiﬁcant pro-
portion of SCD events occur in patients with LVEF
>35%, which underscores the need for improved
risk stratiﬁcation early in the course of acute MI (3).
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acute MI has been associated with scar
burden (4), scar tissue inhomogeneity (5),
as well as electrical abnormalities such
as increased T-wave alternans (6). The
pathophysiological process leading to
SCD or VA is thought to be re-entrant
currents originating in the scar region and
the peri-infarct area (7). Echocardiographic
deformation analysis with assessment of
myocardial dispersion (MD) assessed by
the SD of time to peak longitudinal strain
has been shown to predict arrhythmic
events in patients with ischemic heart dis-
ease undergoing ICD implantation (8).
Global longitudinal strain (GLS) corre-
lates with infarct size (9) and predicts
death and HF after acute MI (10). How-
ever, to the best of our knowledge, no priorstudies have assessed the importance of these echo-
cardiographic deformation parameters in speciﬁc
relation to SCD or VA in a large, unselected,
contemporary population of acute MI. We hypoth-
esized that the early measurement of GLS as
a sensitive measure of myocardial injury, as well
as MD reﬂecting inhomogeneous contraction,
would predict SCD or VA independently and
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METHODS
Study design and patient population. We prospec-
tively included patients referred for invasive coronary
angiography due to either ST-segment elevation or
non–ST-segment elevation MI at 2 tertiary cardiac
centers in the region of Copenhagen, Denmark. All
patients provided written informed consent. Exclu-
sion criteria were age <18 years, noncardiac disease
with a life expectancy <1 year, and an inability to
provide written informed consent. Furthermore,
patients in whom atrial ﬁbrillation, paced rhythm, or
severe aortic stenosis were noted at the time of
echocardiographic examination were excluded from
the analyses.
Information on diabetes, hypertension, history of
ischemic heart disease or MI, and objective signs of
HF (Killip class) were acquired from chart review.
Findings in relation to coronary angiography, in-
cluding culprit lesion, number of diseased vessels,
left main involvement, and type of revascularization
(percutaneous coronary intervention, coronary artery
bypass grafting, or no intervention) were registered.
QRS duration was obtained from 12-lead electro-
cardiography obtained before discharge. Peak tro-
ponin I was measured in 250 patients (25.3%), and
peak troponin T was measured in 738 patients
(74.7%). The study protocol was approved by the
regional scientiﬁc ethics committee (reference no.
H-D-2009-063).
Echocardiography. Echocardiography was performed
within 48 h of admission to the tertiary center.
Echocardiographic cine loops were obtained by
the recording of 3 consecutive heart cycles. All ex-
aminations were performed on a Vivid e9 system
(General Electric, Horten, Norway). Images were
obtained at a frame rate of at least 60 frames/s and
analyzed ofﬂine (Echopac BT 11.1.0, General
Electric). All analyses were performed by a single
experienced operator (M.E.) who was blinded to
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Figure 1. Representative Example of the Calculation of GLS and MD
MD was calculated as the SD of time to peak regional negative strain. ANT ¼ anterior;
GLS ¼ global longitudinal strain; INF ¼ inferior; LAT ¼ lateral; MD ¼ mechanical dispersion;
POST ¼ posterior; SEPT ¼ septal.
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853Volumetric measurements (LVEF, LV end-
diastolic volume [EDV], and LV end-systolic
volume) were determined using the biplane Simp-
son model. LV mass index was calculated from the
LV linear dimensions in the parasternal view. All
volumetric analyses were performed in accordance
with European Association of Echocardiography/
American Society of Echocardiography recom-
mendations (11).
Strain analysis. Two-dimensional speckle tracking
was performed on 3 apical views (long-axis, 4-
chamber, and 2-chamber). Aortic valve closure was
identiﬁed on continuous-wave Doppler recording
through the aortic valve. The region of interest was
adjusted to cover the thickness of the myocardium.
The LV was subsequently divided into 17 segments
covering the entire myocardium, and GLS was
calculated as the mean of the global peak systolic
strain from each of the 3 views. Careful inspection
of tracking and manual correction, if needed, were
performed; if tracking was unsatisfactory, the
segment was excluded from the analysis. If GLS
could be assessed only in 2 of 3 apical projections,
we calculated the overall GLS as the mean of these
2. If GLS could not be assessed in at least 2 of the
apical projections, the patient examination was
classiﬁed as having image quality insufﬁcient for
strain measurements. Mechanical dispersion was
calculated as the SD of the time from the peak R-
wave to peak negative strain during the entire car-
diac cycle in all segments (Fig. 1). Segments without
shortening during the entire cardiac cycle were
excluded. However, segments with stretching in
systole and subsequent shortening were included in
the measurements of time to peak strain. If 6 or
more segments did not have sufﬁcient tracking, the
patient was excluded from the analyses.
Follow-up and endpoint deﬁnition. The primary out-
come was a composite of deﬁnite or suspected SCD,
admission with documented VA, or appropriate ICD
discharge only in patients with a primary prophylactic
ICD. Information on all-causemortalitywas obtained
from theDanish Civil Registration System, and cause
of death was ascertained from hospital and pre-
hospital patient records by 2 independent reviewers
who were blinded to echocardiographic data, and in
cases of disagreement, a third reviewer was consulted.
ICD therapy was evaluated from device interrogation
by an experienced cardiac electrophysiologist blinded
to the echocardiographic data.Nopatientswere lost to
follow-up.
Statistical analyses. All data are reported as mean 
SD or median (ﬁrst and third quartiles [Q1 to Q3]).
Baseline characteristics are given according toquartiles of GLS and MD. Categorical data were
tested with the Cochran-Armitage trend test and
continuous variables analyzed with analysis of vari-
ance or the Kruskal-Wallis test in cases of skewed
distribution. All tests were 2-sided and statistical
signiﬁcance was deﬁned as p < 0.05. Interobserver
and intraobserver reproducibility of GLS and MD
was assessed by two readers (M.E. and U.M.M.) in
20 randomly selected patients by Bland-Altman
analysis (12).
Cause-speciﬁc Cox regression models allowing
for competing risks were used to identify univariate
predictors of the primary composite outcome. These
predictors were then added to a multivariate model
to assess any independent information of GLS and
MD. A ﬁnal parsimonious model was obtained by
backward selection using p < 0.10 for retention.
The competing risk associated with the primary
composite outcome was death from all causes other
than SCD. Unadjusted cumulative incidence curves
were calculated for the primary composite outcome
stratiﬁed by tertiles of GLS and MD. Interactions
were analyzed between the covariates in the ﬁnal
parsimonious model. The added values of GLS and
MD were assessed using reclassiﬁcation analysis,
Table 1. Baseline Characteristics According to Tertiles of GLS
GLS <–15.5%
(n [ 330)
L15.5% < GLS <L12%
(n [ 329)
GLS >–12%
(n [ 329) p Value
Age, yrs 61.15  11.8 61.01  12.1 65.57  11.8 <0.0001
Male 223 (67.6) 255 (77.5) 236 (71.7) 0.0167
Hypertension 133 (40.3) 141 (42.9) 180 (54.7) 0.0004
Previous MI 36 (10.9) 37 (11.2) 49 (14.9) 0.2265
Diabetes 33 (10.0) 42 (12.8) 54 (16.4) 0.0496
Medical history prior to MI
ACEi/ARB 71 (21.5) 74 (22.5) 94 (28.6) 0.0725
Beta-blocker 34 (10.3) 31 (9.4) 48 (14.6) 0.0835
ASA/clopidogrel 43 (13.0) 50 (15.2) 57 (17.3) 0.3073
Killip class >1 14 (4.2) 24 (7.3) 103 (31.3) <0.0001
ECG ﬁndings
HR 67.73  10.7 70.33  11.9 80.01  13.5 <0.0001
QRS duration, ms 94.98  15.6 97.82  18.0 101.06  23.3 0.0008
QTc duration, ms 418.50  36.5 426.60  30.1 431.35  30.1 <0.0001
QRS >120 ms 12 (3.6) 17 (5.2) 29 (8.8) 0.0147
Infarct classiﬁcation
Non-STEMI 133 (40.3) 98 (29.8) 80 (24.3)
<0.0001
STEMI 197 (59.7) 231 (70.2) 249 (75.7)
Troponin T, mg/l 1.0 (0.3–2.5) 2.1 (0.5–4.6) 4.6 (1.6–9.0) <0.0001
Troponin I, mg/l 10.3 (2.7–50.6) 33.9 (8.2–145.2) 136.0 (23.7–277.8) <0.0001
LAD involvement 78 (23.7) 108 (32.8) 213 (64.7) <0.0001
3VD/LM involvement 37 (11.2) 45 (13.7) 78 (23.7) <0.0001
Intervention
No PCI 81 (24.5) 66 (20.1) 62 (18.8)
0.0420PCI 65 (19.7) 52 (15.8) 46 (14.0)
Primary PCI 184 (55.8) 211 (64.1) 221 (67.2)
CABG 21 (6.4) 28 (8.5) 34 (10.3) 0.1842
Echocardiography ﬁndings
LVEDV, ml 80.69  22.7 85.99  25.1 97.93  34.4 <0.0001
LVESV, ml 34.59  12.5 42.15  16.1 58.11  28.4 <0.0001
LVEF, % 57.54  7.3 51.74  8.2 42.55  10.3 <0.0001
LVMI, g/m2 84.83  20.0 89.30  22.5 100.90  30.5 <0.0001
MD, ms 49.39  12.4 56.73  13.9 64.40  18.7 <0.0001
Values are mean  SD, n (%), or median (Q1–Q3).
3VD ¼ 3-vessel disease; ACEi ¼ angiotensin converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; ASA ¼ acetylsalicylic acid; CABG ¼ coronary artery
bypass grafting; ECG ¼ electrocardiography; GLS ¼ global longitudinal strain; LAD ¼ left anterior descending; LM ¼ left main; LVEDV ¼ left ventricular end diastolic
volume; LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ventricular end systolic volume; LVMI ¼ left ventricular mass index; MD ¼ mechanical dispersion;
MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction.
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854with calculations of integrated diagnostic improve-
ment (IDI) and category-free continuous net re-
classiﬁcation improvement (NRI0) allowing for
censored data (13). Landmark analysis was per-
formed at 90 days after the index event. Finally, the
stability of the parsimonious model was assessed by
ﬁtting the model in 1,000 bootstrap replicates of the
original dataset. This allowed for an evaluation ofthe consistency of the associations between the
selected covariates and the outcome when small
changes in the data were introduced. All statistical
analyses were performed using R software (R De-
velopment Core Team 2011 R Foundation, Vienna,
Austria), with the following packages: Survival,
RiskRegression, Hmisc, CAR, survIDINRI, and
Publish.
Figure 2. Clinical Outcomes of GLS
Scatterplot of GLS versus left ventricular (LV) ejection fraction, with plotting of clinical
outcomes. SCD/VA ¼ sudden cardiac death/ventricular arrhythmias. Abbreviation as in
Figure 1.
Figure 3. Clinical Outcomes of MD
Scatterplot of MD versus LV ejection fraction, with plotting of clinical outcomes. Abbrevi-
ations as in Figures 1 and 2.
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855RESULTS
Patient characteristics and outcome. A total of
1,106 patients were enrolled in the study, of whom
56 (5.1%) were excluded prior to strain analyses due
to atrial ﬁbrillation (n ¼ 40), ventricular paced
rhythm (n ¼ 8), or severe aortic stenosis (n ¼ 8). Of
1,054 patients, 66 were excluded due to missing
values in the regional strain traces of >5 segments,
leaving 988 patients (mean age: 62.6  12.1 years;
72% male), with a total of 16,488 tracked segments.
During a median follow-up of 29.7 months (Q1 to
Q3: 23.5 to 32.7), a total of 80 (8.1%) deaths
occurred, of which 26 were attributed to SCD
(32.5%). Three patients (0.3%) were admitted with
VA or successfully resuscitated after SCD, of whom
none died during follow-up and all received a sec-
ondary prophylactic ICD. A total of 30 patients
(3%) had a primary prophylactic ICD implanted
during follow-up, of whom 6 (20%) had appropriate
therapy (shock: 4; antitachycardia pacing: 2). Of the
30 patients with a primary prophylactic ICD, 2
experienced SCD, with 1 patient having previously
received appropriate therapy and 1 without previous
appropriate therapy. Thus, a total of 34 patients
(3.4%) experienced the primary composite outcome
(SCD: 25; VA: 3; appropriate ICD therapy: 6).
Intraobserver and interobserver mean differences
(95% CI) in agreement for GLS were 0.7  2.5%
and 0.05  1.3%, respectively, and for MD
were1.4 7.5 ms and 1.3 10.8 ms, respectively.
Deformation analysis for the prediction of SCD or VA.
Impaired GLS and prolonged MD were associated
with increasing age, higher prevalence of comor-
bidities, wider QRS, larger infarct size, more severe
angiographic ﬁndings, and increasingly worsening
measures of LV systolic function (Table 1, Online
Table 1). The correlation between LVEF and
GLS (r: 0.67; p < 0.0001) was stronger than
between LVEF and MD (r: 0.22; p < 0.0001)
and GLS and MD (r: 0.40; p < 0.0001) (Figs. 2
and 3). Patients experiencing SCD/VA compared
with those without an event were more likely to have
had low LVEF (42.4  13.5% vs. 51.4  10.1%),
impaired GLS (9.9  4.0 ms vs. 13.9 3.5 ms),
and high MD (70.7  29.7 vs. 56.1  15.3)
(Table 2).
On univariate Cox analysis, LVEF (HR: 0.93;
95% CI: 0.90 to 0.96; p < 0.0001), GLS (HR:
1.38; 95% CI: 1.25 to 1.53; p < 0.0001), and MD
(HR/10 ms: 1.38; 95% CI: 1.24 to 1.55; p <
0.0001) were signiﬁcantly associated with SCD/
VA. However, GLS exhibited a higher Wald value
(40.0) compared with MD (32.7) and LVEF (24.9).On multivariate analysis, age (HR: 1.04; 95% CI:
1.01 to 1.08; p ¼ 0.0210), GLS (HR: 1.24; 95%
CI: 1.10 to 1.40; p ¼ 0.0004), and MD (HR/10
Table 2. Baseline Characteristics According to Outcome
No Event
(n [ 900)
SCD or VA
(n [ 34)
Death From
Other Cause
(n [ 54) p Value
Age, yrs 61.7  11.8 69.7  10.3 73.0  10.8 <0.0001
Male 654 (72.7) 23 (67.6) 37 (68.5) 0.6662
Hypertension 399 (44.3) 21 (61.8) 34 (63.0) 0.0048
Previous MI 101 (11.2) 10 (29.4) 11 (20.4) 0.0012
Diabetes 112 (12.4) 6 (17.6) 11 (20.4) 0.1762
Medical history prior to MI
ACEi/ARB 208 (23.1) 12 (35.3) 19 (35.2) 0.0404
Beta-blocker 94 (10.4) 8 (23.5) 11 (20.4) 0.0066
ASA/clopidogrel 125 (13.9) 11 (32.4) 14 (25.9) 0.0010
Killip class >1 108 (12.0) 13 (38.2) 20 (37.0) <0.0001
ECG ﬁndings
HR 72  13 76  17 75  11 0.0412
QRS duration, ms 97  19 108  23 104  19 0.0024
QTc duration, ms 425  33 424  32 433  29 0.1502
QRS >120 ms 45 (5.0) 9 (26.5) 4 (7.4) <0.0001
Infarct classiﬁcation
Non-STEMI 276 (30.7) 14 (41.2) 21 (38.9)
0.2088
STEMI 624 (69.3) 20 (58.8) 33 (61.1)
Troponin T, mg/l 2.1 (0.5–5.2) 5.0 (0.5–10.9) 2.4 (0.3–6.9) 0.2551
Troponin I, mg/l 36.1 (6.8–179.5) 75.0 (15.1–210.0) 30.0 (7.2–91.3) 0.6899
LAD involvement 363 (40.4) 18 (52.9) 18 (33.3) 0.1882
3VD/LM involvement 137 (15.2) 10 (29.4) 13 (24.1) 0.0238
Intervention
No PCI 185 (20.6) 11 (32.4) 13 (24.1)
0.4946PCI 148 (16.4) 6 (17.6) 9 (16.7)
Primary PCI 567 (63.0) 17 (50.0) 32 (59.3)
CABG 73 (8.1) 5 (14.7) 5 (9.3) 0.3855
Echocardiography ﬁndings
LVEDV, ml 87.0  27.4 108.0  40.2 96.1  36.1 0.0004
LVESV, ml 43.5  20.8 64.6  32.6 56.7  30.9 <0.0001
LVEF, % 51.4  10.1 42.4  13.5 43.5  13.4 <0.0001
LVMI, g/m2 90.2  24.4 105.2  32.5 107.9  32.4 <0.0001
GLS, % 13.9  3.5 9.9  4.0 11.7  4.0 <0.0001
MD, ms 56.1  15.3 70.7  29.7 59.6  18.2 0.0018
Values are mean  SD, n (%), or median (Q1–Q3).
Abbreviations as in Table 1.
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856ms: 1.15; 95% CI: 1.01 to 1.31; p ¼ 0.0320) were
independently prognostic in relation to SCD/VA,
while LVEDV and QRS >120 ms were borderline
signiﬁcant (p < 0.10) and thus were retained in the
model as previously described (Table 3). The cu-
mulative incidence functions of SCD/VA according
to tertiles of GLS and MD are shown in Figure 4.
As a sensitivity analysis, we excluded patients
with antitachycardia pacing therapy only from theprimary composite outcome. The results for neither
GLS nor MD on univariate analysis (GLS, HR:
1.38 [95% CI: 1.25 to 1.53; p < 0.0001]; MD, HR/
10 ms: 1.38 [95% CI: 1.24 to 1.55; p < 0.0001]) or
on multivariate analyses (GLS, HR: 1.24 [95% CI:
1.10 to 1.40; p ¼ 0.0004]; MD, HR/10 ms: 1.15
[95% CI: 1.01 to 1.31; p ¼ 0.0320]) changed sig-
niﬁcantly as a result of this.
Subgroup analyses according to LVEF. Among pa-
tients with LVEF <35% (n ¼ 84), SCD/VA
occurred in 11 patients (13.1%) during follow-up,
and 67.6% (n ¼ 23) of the SCD/VA events oc-
curred in patients with LVEF >35% (n ¼ 904). In
patients with LVEF <35%, only GLS (HR: 1.64;
95% CI: 1.13 to 2.39; p ¼ 0.0092) and MD
(HR/10 ms: 1.17; 95% CI: 1.01 to 1.37; p ¼
0.0413) retained independent prognostic infor-
mation. In patients with LVEF >35%, age (HR:
1.05; 95% CI: 1.01 to 1.09; p ¼ 0.0104), LVEDV
(HR/10-ml increase: 1.21; 95% CI: 1.06 to 1.38;
p ¼ 0.0045), and GLS (HR: 1.21; 95% CI: 1.05
to 1.40; p ¼ 0.0092) remained independently
prognostic (Table 4).
Reclassiﬁcation. Adding GLS to a model contain-
ing the signiﬁcant and borderline signiﬁcant vari-
ables from the multivariate model age, LVEDV and
QRS >120 ms resulted in signiﬁcant IDI (4.4%;
p < 0.05) and NRI0 (29.6%; p < 0.05) (data not
shown). The subsequent addition of MD did not
yield further improvement in risk classiﬁcation, with
IDI ¼ 0.02% (p ¼ NS) and NRI0 ¼ 0.02%
(p ¼ NS). Because the multivariate model was data
driven and derived in our population only, reclas-
siﬁcation was also assessed by adding GLS and MD
to LVEF and Killip class >1, which are widely used
in daily clinical risk stratiﬁcation. When adding
GLS to LVEF and Killip class >1, signiﬁcant
improvement in reclassiﬁcation occurred (IDI: 2.4%
[p < 0.05]; NRI0: 21.0% [p < 0.05]), whereas
adding MD to LVEF, Killip class >1 and GLS
resulted in no further improvement (IDI: 2.4%
[p ¼ NS]; and NRI0: 0.3% [p ¼ NS]). Landmark
analysis at 90 days’ follow-up demonstrated that
GLS was independently associated with SCD/VA
(HR: 1.85; CI: 1.23 to 2.79; p ¼ 0.003) after
adjustment for LVEF and Killip class >1. However,
when replacing GLS with MD, there was only a
borderline signiﬁcant association with short-term
risk for SCD/VA (HR: 1.03; 95% CI: 1.00 to
1.05; p ¼ 0.055). Bootstrap validation of the parsi-
monious model in 1,000 randomly regenerated
samples of the original dataset revealed that GLS
was consistently associated with SCD/VA, whereas
the other covariates in the model were less so (Fig. 5).
Table 3. Univariate and Multivariate HR (95% CI) for the Primary Composite Endpoint SCD/VA
Covariate
Univariate Analysis Multivariate Analysis
HR 95% CI p Value HR 95% CI p Value
Age per yr 1.06 1.03–1.09 0.0003 1.04 1.01–1.08 0.0210
Male 0.77 0.38–1.58 0.4807
Killip class >1 4.29 2.15–8.58 <0.0001
LAD involvement 1.43 0.89–2.31 0.1386
3VD or LM involvement 2.27 1.09–4.75 0.0293
Diabetes 1.44 0.60–3.49 0.4138
Previous MI 3.08 1.47–6.45 0.0028
Troponin 1.26 0.92–1.71 0.1462
QRS >120 ms 6.30 2.94–13.49 <0.0001 2.20 0.95–5.14 0.0641
LVEF 0.93 0.90–0.96 <0.0001
LVEDV/10-ml increase 1.21 1.11–1.32 <0.0001 1.11 1.00–1.23 0.0612
LVESV/10-ml increase 1.28 1.17–1.40 <0.0001
WMSI/0.1 increase 1.39 1.25–1.55 <0.0001
GLS 1.38 1.25–1.53 <0.0001 1.24 1.10–1.40 0.0004
MD/10 ms 1.38 1.24–1.55 <0.0001 1.15 1.01–1.31 0.0320
CI ¼ conﬁdence interval; HR ¼ hazard ratio; SCD/VA ¼ sudden cardiac death/ventricular arrhythmia; WMSI ¼ wall motion score index; other abbreviations as in
Table 1.
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857DISCUSS ION
This study demonstrated in a large cohort of patients
with acute MI that early measurement of GLS was
an independent and consistent predictor of SCD/
VA. Adding GLS to already known risk factors
resulted in signiﬁcantly improved risk reclassiﬁca-
tion, whereas MD as a marker of contraction in
homogeneity provided less additional information.
GLS and MD as markers of arrhythmic risk. VA and
SCD after acute MI and in patients with chronicFigure 4. Cumulative Incidence Function of the Primary Composite
Cumulative incidence stratiﬁed according to tertiles of GLS (left) and Mischemic HF have been shown to be closely related
to the extent of myocardial scarring and scar tissue
heterogeneity assessed by cardiac magnetic resonance
(4). The border zone between viable myocardium
and necrotic scar tissue contains areas where viable
and necrotic areas are interwoven (14,15), which
slows conduction and forms a substrate of post-MI
VA (16). The close relationship between GLS and
infarct size after acute MI and in chronic ischemic
heart disease has previously been demonstrated
(9,17). Regional differences in myocardial electricalOutcome SCD/VA
D (right). Abbreviations as in Figures 1 and 2.
Table 4. Multivariate HR (95% CI) for the Primary Composite
Endpoint SCD/VA according to LVEF <35% and LVEF >35%
Covariate HR 95% CI p Value
LVEF <35%
Age/yrs 1.04 0.96–1.12 0.3201
MD/10 ms 1.17 1.01–1.37 0.0413
QRS >120 ms 2.12 0.57–7.89 0.2634
LVEDV/10-ml increase 0.93 0.76–1.13 0.4585
GLS 1.64 1.13–2.39 0.0092
LVEF >35%
Age/yrs 1.05 1.01–1.09 0.0104
MD/10 ms 0.99 0.76–1.29 0.9387
QRS >120 ms 1.74 0.52–5.78 0.3651
LVEDV/10-ml increase 1.21 1.06–1.38 0.0045
GLS 1.21 1.05–1.40 0.0092
Abbreviations as in Tables 1 and 3.
Figure 5.
The mode
>120 ms
original d
model an
borderline
as p > 0.
Ersbøll et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 8 , 2 0 1 3
Early Deformation and Sudden Cardiac Death in MI A U G U S T 2 0 1 3 : 8 5 1 – 6 0
858activity caused by infarct tissue could be reﬂected by a
more heterogeneous myocardial contraction pattern,
which has been shown to predict appropriate ICD
therapy in post-MI patients with both primary and
secondary prophylactic indications (8). We demon-
strated that GLS was an independent predictor ofBar Plot of Bootstrap Validation of the Final Parsimonious Model
l including age, GLS, LV end-diastolic volume (EDV), MD, and QRS
was ﬁtted in 1,000 randomly regenerated bootstrap samples of the
ataset. The signiﬁcance level of each covariate was assessed in each
d counted. Signiﬁcant association (green) was deﬁned as p < 0.05;
signiﬁcance (blue), as 0.05 < p < 0.10; and nonsigniﬁcance (pink),
10. Abbreviations as in Figures 1 and 2.SCD/VA and superior to existing echocardiographic
parameters, including LVEF. Furthermore, MD as a
measure of heterogeneous contraction was also
independently related to SCD/VA, albeit not as
consistently and strongly as GLS. Adding MD to a
model already including GLS did not signiﬁcantly
improve reclassiﬁcation, and analysis of bootstrap
replicates revealed that MD was a less stable pre-
dictor than was GLS.
Our ﬁndings are partly in contrast to those from
the study by Haugaa et al. (8). Impaired myocardial
segments with smaller strain amplitude often exhibit
a ﬂatter curve shape, with smaller strain rate values
and prolonged time to peak strain. Identifying the
time to peak negative value in such segments will
inherently be associated with more variation than in
a viable segment with normal deformation. Thus,
measurement error alone will contribute to increased
values of MD in an LV, with several segments
exhibiting impaired strain. The independent prog-
nostic value of MD found in our study, despite these
limitations, conﬁrm that the important prognostic
information speciﬁc to SCD/VA described by
Haugaa et al. (8) also pertains to patients with acute
MI. However, our bootstrap validation suggests that
MD may be a difﬁcult parameter to integrate into
daily clinical practice or as a selection criterion for
future randomized trials. Haugaa et al. (8) measured
MD in patients at varying time points after the MI
and the time course of MD after acute MI has not
been studied. However, it has been demonstrated,
that GLS improves in most patients over 6 to 12
months (18). Thus, the prognostic value of MD
relative to GLS might improve with increasing time
from the index MI. Indeed our landmark analysis
suggests that GLS but not MD was signiﬁcantly
associated with short-term risk for SCD/VA within
the ﬁrst 90 days after MI. A recent multicenter
study by Haugaa et al. (19) with contributions from
our group suggests that with further time elapsed
from the index acute MI, MD may become
increasingly important relative to GLS.
Arrhythmia risk prediction after acute MI. The risk
for SCD in patients with reduced LVEF is highest
in the early aftermath of acute MI as demonstrated
in the VALIANT (Valsartan in Acute Myocardial
Infarction Trial) trial (2). A substudy of that trial
suggested that the cause of SCD in the early phase
after acute MI was dominated by recurrent MI
and cardiac rupture, whereas after 3 months,
arrhythmic SCD became more prevalent (20).
DINAMIT (Deﬁbrillator in Acute Myocardial
Infarction Trial) failed to demonstrate an overall
survival advantage with ICD implantation early
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859after MI (21). Accordingly, guidelines recommend
ICD implantation in eligible patients at least
40 days after the MI (1). However, in both of
these trials, only patients with depressed LVEF
(DINAMIT) and or clinical HF (VALIANT) were
included; thus, the estimates of the relative pro-
portions of SCD etiologies may not necessarily apply
to our contemporary MI population, in which only
8.5% had LVEF <35%. The conundrum of greater
early risk for SCD/VA after acute MI, lack of sur-
vival advantage with early ICD implantation in low
LVEF, and the potential for substantial recovery in
LV function over time poses a signiﬁcant challenge.
Adding deformation-based indices of LV function
to LVEF in the early phase of acute MI could
potentially identify high-risk subjects in whom
wearable deﬁbrillators (22) could be worn until such
time as either LV function is improved or ICD
implantation is indicated.
Cardiac magnetic resonance remains the gold
standard for quantitative measurement of myocardial
scarring. However, due to limited healthcare re-
sources and availability of magnetic resonance im-
aging, implementing an evaluation of scar burden in
all patients with acute MI is prohibitive. The po-
tential gatekeeping role of early echocardiographic
deformation imaging in more complex imaging
strategies in patients with acute MI should be
investigated further.
Study limitations. The primary outcome SCD/VA
was rare in our study, which highlights the difﬁ-
culties of studying novel SCD/VA risk-stratiﬁcation
tools in a prospective way in acute MI. The low
number of events renders the multivariate models
uncertain, with a high risk for overﬁtting andpotentially discarding covariates with real prognostic
value due to low power. The etiology of SCD may
not necessarily be ventricular tachyarrhythmia ori-
ginating in myocardial scar areas; indeed new
MI triggering ventricular tachycardia or ventricular
ﬁbrillation may account for a signiﬁcant number of
SCD events. Myocardial rupture has also been
shown to account for a signiﬁcant proportion of
early SCD, although this complication may be more
common in the subset of patients with low LVEF
(20). The high degree atrioventricular block may
account for a signiﬁcant proportion of SCD (23),
and the relationship between conduction abnor-
malities after acute MI and deformation patterns is
unresolved. Measurements of GLS and MD were
performed using a proprietary system (EchoPac,
General Electric); however, both GLS and regional
myocardial timing intervals can be measured with
good reproducibility across different platforms and
software algorithms (24,25).
CONCLUS IONS
Early assessment of GLS and MD signiﬁcantly
improves the prediction of SCD/VA in contem-
porarily managed patients with acute MI. GLS
appears to be a particularly promising measure of
risk for SCD/VA and, importantly, acts as an early
identiﬁer of individuals with LVEF <35% at low
risk for malignant arrhythmias.
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